{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=pitavastatin&page=2",
    "query": {
      "intervention": "pitavastatin",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=pitavastatin&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-30T03:04:36.699Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02344290",
      "title": "Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV",
        "Cardiovascular Diseases"
      ],
      "interventions": [
        {
          "name": "Pitavastatin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "40 Years to 75 Years"
      },
      "enrollment_count": 7769,
      "start_date": "2015-03-26",
      "completion_date": "2023-08-21",
      "has_results": true,
      "last_update_posted_date": "2025-09-04",
      "last_synced_at": "2026-09-30T03:04:36.699Z",
      "location_count": 91,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 59 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02344290"
    },
    {
      "nct_id": "NCT01890967",
      "title": "A Study of LY3015014 in Participants With High Cholesterol",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hypercholesterolemia"
      ],
      "interventions": [
        {
          "name": "LY3015014",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Statin",
          "type": "DRUG"
        },
        {
          "name": "Ezetimibe",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 527,
      "start_date": "2013-06",
      "completion_date": "2014-06",
      "has_results": true,
      "last_update_posted_date": "2019-09-18",
      "last_synced_at": "2026-09-30T03:04:36.699Z",
      "location_count": 15,
      "location_summary": "Encino, California • Lancaster, California • Spring Valley, California + 12 more",
      "locations": [
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Lancaster",
          "state": "California"
        },
        {
          "city": "Spring Valley",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Safety Harbor",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01890967"
    },
    {
      "nct_id": "NCT02799758",
      "title": "Efficacy & Long-term Safety Comparison Study of NK-104-CR & Livalo® IR With Primary Hyperlipidemia or Mixed Dyslipidemia",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hyperlipidemia",
        "Dyslipidemia"
      ],
      "interventions": [
        {
          "name": "NK-104-CR",
          "type": "DRUG"
        },
        {
          "name": "Livalo® IR",
          "type": "DRUG"
        },
        {
          "name": "Placebo (for NK-104-CR)",
          "type": "DRUG"
        },
        {
          "name": "Placebo (for Livalo® IR)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kowa Research Institute, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 0,
      "start_date": "2016-02",
      "completion_date": "2017-11",
      "has_results": false,
      "last_update_posted_date": "2021-05-10",
      "last_synced_at": "2026-09-30T03:04:36.699Z",
      "location_count": 69,
      "location_summary": "Foley, Alabama • Huntsville, Alabama • Montgomery, Alabama + 66 more",
      "locations": [
        {
          "city": "Foley",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Muscle Shoals",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02799758"
    },
    {
      "nct_id": "NCT01043094",
      "title": "Safety, Tolerability, and Pharmacokinetic of Single Dose of Pitavastatin 4 mg in Severe Renal Patients Versus Healthy Adult Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Severe Renal Impairment"
      ],
      "interventions": [
        {
          "name": "Pitavastatin 4mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kowa Research Institute, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2009-12",
      "completion_date": "2010-12",
      "has_results": true,
      "last_update_posted_date": "2012-08-13",
      "last_synced_at": "2026-09-30T03:04:36.699Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01043094"
    },
    {
      "nct_id": "NCT02290106",
      "title": "Effects of Pitavastatin on Insulin Sensitivity and Liver Fat",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Obesity",
        "Fatty Liver, Nonalcoholic"
      ],
      "interventions": [
        {
          "name": "pitavastatin",
          "type": "DRUG"
        },
        {
          "name": "PLACEBO",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "65 Years",
        "sex": "MALE",
        "summary": "40 Years to 65 Years · Male only"
      },
      "enrollment_count": 50,
      "start_date": "2015-03-02",
      "completion_date": "2018-04-30",
      "has_results": true,
      "last_update_posted_date": "2019-07-02",
      "last_synced_at": "2026-09-30T03:04:36.699Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02290106"
    },
    {
      "nct_id": "NCT01422382",
      "title": "Drug-Drug Interaction of Cardizem LA (Diltiazem Hydrochloride) on Pitavastatin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Pitavastatin (NK-104)",
          "type": "DRUG"
        },
        {
          "name": "Diltiazem (Cardizem LA) 240 mg QD",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kowa Research Institute, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 28,
      "start_date": "2011-05",
      "completion_date": "2011-07",
      "has_results": true,
      "last_update_posted_date": "2012-07-13",
      "last_synced_at": "2026-09-30T03:04:36.699Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01422382"
    },
    {
      "nct_id": "NCT05334108",
      "title": "Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates for Drug Metabolism and Transport",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Drug Interaction"
      ],
      "interventions": [
        {
          "name": "Ecopipam",
          "type": "DRUG"
        },
        {
          "name": "Cohort 1 Probe Substrate Cocktail",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Cohort 2 Probe Substrate",
          "type": "DRUG"
        },
        {
          "name": "Cohort 3 Probe Substrate Cocktail",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Emalex Biosciences Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 56,
      "start_date": "2022-04-26",
      "completion_date": "2022-08-26",
      "has_results": false,
      "last_update_posted_date": "2022-12-12",
      "last_synced_at": "2026-09-30T03:04:36.699Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05334108"
    },
    {
      "nct_id": "NCT06813924",
      "title": "A Research Study of the Effect of Etavopivat on Other Drugs in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers Sickle Cell Disease, Thalassemia"
      ],
      "interventions": [
        {
          "name": "Etavopivat",
          "type": "DRUG"
        },
        {
          "name": "Digoxin",
          "type": "DRUG"
        },
        {
          "name": "Pitavastatin",
          "type": "DRUG"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        },
        {
          "name": "Midazolam",
          "type": "DRUG"
        },
        {
          "name": "Rosuvastatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 37,
      "start_date": "2025-02-06",
      "completion_date": "2025-05-27",
      "has_results": false,
      "last_update_posted_date": "2026-09-29",
      "last_synced_at": "2026-09-30T03:04:36.699Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06813924"
    },
    {
      "nct_id": "NCT03070223",
      "title": "PREPARE (A5361s) Ancillary Study of REPRIEVE (A5332)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV-1 Infection"
      ],
      "interventions": [
        {
          "name": "Pitavastatin",
          "type": "DRUG"
        },
        {
          "name": "Placebos",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "40 Years to 75 Years"
      },
      "enrollment_count": 602,
      "start_date": "2017-03-14",
      "completion_date": "2023-08-21",
      "has_results": true,
      "last_update_posted_date": "2024-10-28",
      "last_synced_at": "2026-09-30T03:04:36.699Z",
      "location_count": 30,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • San Diego, California + 22 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03070223"
    },
    {
      "nct_id": "NCT03311841",
      "title": "Pharmacokinetics of Midazolam, Dabigatran, Pitavastatin, Atorvastatin, and Rosuvastatin in Participants With Renal Insufficiency in the Presence and Absence of Rifampin (MK-0000-386)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Renal Insufficiency"
      ],
      "interventions": [
        {
          "name": "Midazolam oral solution",
          "type": "DRUG"
        },
        {
          "name": "Dabigatran and pitavastatin oral solution",
          "type": "DRUG"
        },
        {
          "name": "Atorvastatin and rosuvastatin oral solution",
          "type": "DRUG"
        },
        {
          "name": "Rifampin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "78 Years",
        "sex": "ALL",
        "summary": "18 Years to 78 Years"
      },
      "enrollment_count": 32,
      "start_date": "2018-03-01",
      "completion_date": "2018-08-02",
      "has_results": true,
      "last_update_posted_date": "2020-01-09",
      "last_synced_at": "2026-09-30T03:04:36.699Z",
      "location_count": 2,
      "location_summary": "Hialeah, Florida • Orlando, Florida",
      "locations": [
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03311841"
    }
  ]
}